the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
Official Title Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)
Principal Investigator Szmulewitz, Russell
Brief Summary This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate cancer).
Gender Male
Ages 18 Years
Enrollment 190
Accepts Healthy Volunteers No
Lead Sponsor Dana-Farber Cancer InstituteOther
Collaborator Janssen PharmaceuticaIndustry
Study Design
Study Phase Phase 2
Study Type Interventional
Contact Name Paul Nguyen, MD
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Prostate Cancer
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI